Frangos Jason E, Kimball Alexa B
The Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA.
Expert Opin Pharmacother. 2008 Aug;9(11):2001-7. doi: 10.1517/14656566.9.11.2001.
Topical corticosteroids are the most common treatment modality for patients with psoriasis and atopic dermatitis; however, the efficacy of topical corticosteroids is often hampered by barriers to patient adherence, such as lack of efficacy, side effects and inconvenience. Recently published studies have investigated the safety and efficacy of a novel emollient foam (EF) formulation of clobetasol propionate (CP), a class I topical corticosteroid in psoriasis and atopic dermatitis.
To summarize recent literature on CP EF foam, and to evaluate recent Phase II and III clinical trials of CP EF foam in psoriasis and atopic dermatitis.
The MEDLINE (1950 - January 2008) database was searched using the following terms: 'clobetasol propionate foam', 'topical corticosteroids', 'topical glucocorticoids', 'psoriasis' and 'atopic dermatitis'. Results were evaluated for relevance and quality, and additional references were obtained from bibliographies of selected articles.
CP EF foam appears to be safe and effective for corticosteroid-responsive dermatoses in adults and children > or = 12 years of age. As compared to its hydroethanolic foam predecessor, CP EF presents a potential advance for patients who are less likely to tolerate alcohol-based foam. As alcohol-based foams can be irritating and cause stinging in non-hair-bearing areas, this new emollient formulation has the potential to widen the use of CP foam to more patients with atopic dermatitis and to more non-scalp body sites in patients with psoriasis.
外用糖皮质激素是银屑病和特应性皮炎患者最常用的治疗方式；然而，外用糖皮质激素的疗效常因患者依从性障碍而受到影响，如疗效欠佳、副作用及不便等。最近发表的研究探讨了丙酸氯倍他索（一种I类外用糖皮质激素）新型润肤泡沫（EF）制剂在银屑病和特应性皮炎中的安全性和疗效。
总结近期关于丙酸氯倍他索EF泡沫的文献，并评估其在银屑病和特应性皮炎中的II期和III期临床试验。
使用以下检索词搜索MEDLINE（1950年 - 2008年1月）数据库：“丙酸氯倍他索泡沫”、“外用糖皮质激素”、“外用糖皮质类固醇”、“银屑病”和“特应性皮炎”。对结果进行相关性和质量评估，并从所选文章的参考文献中获取其他参考文献。
丙酸氯倍他索EF泡沫对于成人及12岁及以上儿童的糖皮质激素反应性皮肤病似乎安全有效。与之前的含乙醇泡沫制剂相比，丙酸氯倍他索EF泡沫为耐受性较差的患者带来了潜在的进展。由于含乙醇泡沫可能具有刺激性并在无毛部位引起刺痛，这种新型润肤制剂有可能将丙酸氯倍他索泡沫的使用范围扩大到更多特应性皮炎患者以及更多银屑病患者的非头皮身体部位。
